RPCEC00000393尚未招募2 期
Evaluation of the effect and safety terapeutic of Jusvinza in severe patients with COVID-19
Center for Genetic Engineering and Biotechnology (CIGB), Havana0 个研究点目标入组 108 人开始时间: 2021年10月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial. Masking: Open. Control group: Active. Assignment: Parallel. Purpose: Treatment
入排标准
- 年龄范围
- 19 years 至 one（—）
- 性别
- All
入选标准
- •1. Age = 19.
- •2. Virologial diagnosis by RT-PCR to SARS-Cov-2.
- •3. Patients with serious status.
- •4. Willingness of the patient through informed consent
排除标准
- •1. Patients with kidney disease on hemodialysis.
- •2. Known hypersensitivity to any of the components of the formulations under study
- •3. Pregnancy or breastfeeding.
研究者
相似试验
尚未招募
2 期
VALERGEN-combination of routes- Asthma-Adults-Phase IIAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000298ational Center of Bioproducts (BioCen)180
招募中
1 期
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes MellitusDiabetes Mellitus, Type 1Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System DiseasesDiabetes MellitusType 1 diabetes mellitusRPCEC00000225Center of Molecular Immunology (CIM)40
尚未招募
1 期
euroEPO – Type 2 Spinocerebellar Ataxia Phase I-IIType 2 Spinocerebellar AtaxiaRPCEC00000187Center of Molecular Immunology (CIM), CIMAB34
已完成
不适用
Evaulation of the clinical efficacy and safety of the combined administration of Imidafenacin and Tamsulosin in BPH patients (in which OAB symptoms remain) who did not respond to alpha-1 blocker monotherapy.Overactive bladderJPRN-UMIN000005012Department of Urology, University of Yamanashi, School of Medicine300
进行中（未招募）
1 期
Evaluation of the safety and efficacy of the treatment of chronic wounds in diabetic foot syndrome with the use of autologous stem cells isolated from adipose tissue - within the project: Therapeutic potential of adipose-derived stem cells, proven in clinical trials and examined in vitro - rationale for banking of well characterized cells”MedDRA version: 20.0 Level: LLT Classification code 10012664 Term: Diabetic foot ulcer System Organ Class: 100000004858Diabetic foot ulcerEUCTR2016-004109-15-PLMedical University of Warsaw50